Amphastar P (AMPH)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 169,378 | 114,863 | 82,746 | 4,943 | 62,662 |
| Revenue | US$ in thousands | 644,395 | 498,987 | 437,768 | 349,846 | 322,357 |
| Pretax margin | 26.28% | 23.02% | 18.90% | 1.41% | 19.44% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $169,378K ÷ $644,395K
= 26.28%
The pretax margin of Amphastar Pharmaceuticals Inc has shown a fluctuating trend over the past five years. In 2023, the pretax margin increased to 26.28%, marking a significant improvement from the previous year's 23.02%. This indicates that the company was able to effectively manage its operating expenses relative to its revenue before accounting for taxes.
Compared to 2021 and 2020, where the pretax margin was 19.17% and 1.33% respectively, the substantial increase in 2023 demonstrates a notable enhancement in the company's profitability. The pretax margin in 2019 was 18.68%, showing that the margin in 2023 was slightly higher.
Overall, the rising trend in pretax margin in 2023 signifies improved efficiency in controlling costs and generating higher profits before tax compared to previous years. It suggests that the company's operational performance has strengthened, potentially leading to better financial health and overall performance.
Peer comparison
Dec 31, 2023